Prof Wiedermann - January presentation in SF, page-70

WAG

I agree with you.  IMU has been very bullish this year, we're beyond immune response and safety being enough to keep the market happy.  

P2 is similar to p1b, same dose and with cisplatin etc.  They've added extra patients to the p1b third cohort, if they can't find some good indication of efficacy in there somewhere, it's a long and uneasy wait until the P2 results.  People will sell, the SP will drop and drift IMO.  

Good efficacy here is a good step towards validating the whole platform and raises the potential for an early deal, incentive to buy in and stay in.

Cheers